Alzheimers disease diagnostics and therapeutics market

Alzheimer’s disease diagnostics and therapeutics Market, by Product (Therapeutics (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Others) and Diagnostics (Brain Imaging, CSF Test for Alzheimer’s Disease)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Jan 2023
CMI5181
194 Pages
Excel & Pdf
Pharmaceutical

Summary

Alzheimer's disease is a neurodegenerative condition that typically develops gradually and gets worse over time. It is a form of dementia that progresses over time, causing a person's capacity for independent functioning to be disrupted by a steady decline in thinking, behavioural, and social abilities. Alzheimer's disease has no known cure, but there are treatments that may slow down the disease's progression as well as medication and non-medication options that could help manage symptoms.

Global Alzheimer’s disease diagnostics and therapeutics market is estimated to be valued at US$ 6,231.1million in 2022 and is expected to exhibit a CAGR of 5.4% during the forecast period (2022-2030).

Figure 1. Global Alzheimer’s disease Diagnostics and Therapeutics Market Share (%), By Product, 2022

Global Alzheimer’s disease Diagnostics and Therapeutics Market- Drivers

Increase in the prevalence of Alzheimer’s disease in the old age population is expected to drive the market for the forecast period.

According to Alzheimer's Association, April 2022, an estimated 6.5 million people age 65 and older in 2021 were living with Alzheimer's in the U.S. among which 73% were aged 75 or older.

Key players are focusing on providing new diagnostic tests which will drive the market growth during the forecast period. For instance, Attyloid GmbH, a biotechnology company, offers a biomarker-based laboratory test sFIDA (surface-based fluorescence intensity distribution analysis), for diagnosing Alzheimer’s disease. sFIDA can identify and quantify Aβ oligomers. These small protein aggregates play a significant role in the development and prognosis of Alzheimer’s disease. By sFIDA, differentiation between control samples and AD patient is easily possible.

Alzheimer’s disease Diagnostics and Therapeutics Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 6,231.1 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	5.4 %	2030 Value Projection:	US$ 9,503.1 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Product: Therapeutics (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Others), Diagnostics (Brain Imaging, CSF Test for Alzheimer’s Disease)
Companies covered:	Luye Pharma Group, Vigil Neuroscience, Inc., Grifols, S.A., AbbVie Inc., Zydus Lifesciences Ltd., Merck KGaA, F. Hoffmann-La Roche Ltd., Novartis AG, Johnson & Johnson, Eli Lilly and Company, Biogen Inc., Siemens Healthcare GmbH, Merz Pharma, Eisai Co. Ltd., Lupin Limited, Teva Pharmaceutical Industries Ltd., Apotex Inc., Corium, Inc., Supernus Pharmaceuticals, Inc.
Growth Drivers:	Increase in the prevalence of Alzheimer’s disease Launch of novel diagnostic test
Restraints & Challenges:	Uncertainty, failure, and discontinuation of the clinical trials of Alzheimer's drugs

Figure 2. Global Alzheimer’s disease Diagnostics and Therapeutics Market Share (%), by Region, 2022

Global Alzheimer’s disease Diagnostics and Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another.

The rising cases of COVID-19 are expected to have a short-term negative impact on diagnostic rates of Alzheimer's disease. The short-term effects on the market are less prominent; however, the adverse impacts of COVID-19 on the global economy can have significant effects on the market.

Global Alzheimer’s disease Diagnostics and Therapeutics Market: Key Developments

In October 2021, Salk Institute, a research institute in California, U.S., initiated a phase 1 clinical trial of the investigational Alzheimer’s drug CMS121 to evaluate its safety in humans.

Moreover, In June, 2021, Biogen, a multinational biotechnology company, and Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., announced a range of programs/initiatives intended to support access for all qualified patients, including traditionally underserved populations

Global Alzheimer’s disease Diagnostics and Therapeutics Market: Restraint

The uncertainty, failure, and discontinuation of the clinical trials of Alzheimer's drugs lead to the availability of limited treatment alternatives. This increases the costs related to research and development. Hence, it is expected to restrain the market growth. For instance, Amgen Inc. and Novartis AG discontinued their Phase 2 clinical trial for CNP520 (umibecestat), a BACE1 inhibitor for Alzheimer's disease, in July 2019, due to the lack of desired results.

Global Alzheimer’s disease Diagnostics and Therapeutics Market- Key Players

Major players operating in the global Alzheimer’s disease diagnostics and therapeutics market include Luye Pharma Group, Vigil Neuroscience, Inc., Grifols, S.A., AbbVie Inc., Zydus Lifesciences Ltd., Merck KGaA, F. Hoffmann-La Roche Ltd., Novartis AG, Johnson & Johnson, Eli Lilly and Company, Biogen Inc., Siemens Healthcare GmbH, Merz Pharma, Eisai Co. Ltd., Lupin Limited, Teva Pharmaceutical Industries Ltd., Apotex Inc., Corium, Inc., Supernus Pharmaceuticals, Inc.

Table of Content

Table of Contents

*Browse 16 market data tables and 18 figures on "Global Alzheimer’s Disease Diagnostics and Therapeutics Market” - forecast to 2030

Segmentation

Detailed Segmentation:

Global Alzheimer’s Disease Diagnostics And Therapeutics Market, By Product:
- Therapeutics
  - Cholinesterase Inhibitors
  - NMDA Receptor Antagonists
  - Others
- Diagnostics
  - Brain Imaging
  - CSF Test for Alzheimer’s Disease
Global Alzheimer’s Disease Diagnostics And Therapeutics Market, By Region:
- North America
  - By Product
    - Therapeutics
      - Cholinesterase Inhibitors
      - NMDA Receptor Antagonists
      - Others
    - Diagnostics
      - Brain Imaging
      - CSF Test for Alzheimer’s Disease
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Product
    - Therapeutics
      - Cholinesterase Inhibitors
      - NMDA Receptor Antagonists
      - Others
    - Diagnostics
      - Brain Imaging
      - CSF Test for Alzheimer’s Disease
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Product
    - Therapeutics
      - Cholinesterase Inhibitors
      - NMDA Receptor Antagonists
      - Others
    - Diagnostics
      - Brain Imaging
      - CSF Test for Alzheimer’s Disease
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Product
    - Therapeutics
      - Cholinesterase Inhibitors
      - NMDA Receptor Antagonists
      - Others
    - Diagnostics
      - Brain Imaging
      - CSF Test for Alzheimer’s Disease
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Product
    - Therapeutics
      - Cholinesterase Inhibitors
      - NMDA Receptor Antagonists
      - Others
    - Diagnostics
      - Brain Imaging
      - CSF Test for Alzheimer’s Disease
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Product
    - Therapeutics
      - Cholinesterase Inhibitors
      - NMDA Receptor Antagonists
      - Others
    - Diagnostics
      - Brain Imaging
      - CSF Test for Alzheimer’s Disease
  - By Region/Country
    - South Africa
    - Central Africa
    - North Africa

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global Alzheimer’s disease diagnostics and therapeutics market during the forecast period (2022-2030)?

Global Alzheimer’s disease diagnostics and therapeutics market size is estimated to be valued at US$ 6,231.1 million in 2022 and is expected to exhibit a CAGR of 5.4% between 2022 and 2030.

What are the major factors driving the market growth?

Factors such as increase in the prevalence of Alzheimer’s disease and launch of novel diagnostic test are expected to drive the market growth.

Which is the leading product segment in the market?

Diagnostics is the leading product segment in the market.

• What are the key factors hampering growth of the market?

The major factors hampering growth of the market include uncertainty, failure, and discontinuation of the clinical trials of Alzheimer's drugs.

Which are the major players operating in the market?

Major players operating in the market include Luye Pharma Group, Vigil Neuroscience, Inc., Grifols, S.A., AbbVie Inc., Zydus Lifesciences Ltd., Merck KGaA, F. Hoffmann-La Roche Ltd., Novartis AG, Johnson & Johnson, Eli Lilly and Company, Biogen Inc., Siemens Healthcare GmbH, Merz Pharma, Eisai Co. Ltd., Lupin Limited, Teva Pharmaceutical Industries Ltd., Apotex Inc., Corium, Inc., Supernus Pharmaceuticals, Inc.